Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
:APS
APS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$4.36 - C$77.10
Previous CloseN/A
Volume48.76K
Average Volume (3M)65.57K
Market Cap
C$9.35M
Enterprise ValueC$13.56M
Total Cash (Recent Filing)$15.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.12
Next Earnings
Mar 25, 2025EPS Estimate
-9.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-124.30
Shares Outstanding2,143,372
10 Day Avg. Volume114,971
30 Day Avg. Volume65,567
Standard Deviation2.10
R-Squared0.00027
Alpha0.20
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
C$10.51Price Target Upside141.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Efficacy In TreatmentTwo FLT3-WT patients achieved complete remissions by the end of Cycle 1.
Potential For Broader UseThe TUSCANY trial could position TUS as a promising combination therapy for larger AML populations, avoiding the toxicities observed with other agents.
Safety And TolerabilityThe absence of conspicuous safety signals is an indication of TUS's and the combo therapy's favorable safety and tolerability.
Bears Say
---
Options Prices
Currently, No data available
---
Ownership Overview
1.19% Insiders
<0.01% Mutual Funds
6.36% Other Institutional Investors
92.46% Public Companies and Individual Investors
APS FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$4.36 and its highest was C$77.10 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is C$9.35M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Mar 25, 2025 which is in 21 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Nov 08, 2024. The company reported -C$16.022 earnings per share for the quarter, beating the consensus estimate of -C$27.714 by C$11.692.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -9.82.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,143,372 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -C$16.022 in its last earnings report, beating expectations of -C$27.714. Following the earnings report the stock price went up 1.852%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Currently, no hedge funds are holding shares in TSE:APS
---
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
APS Stock 12 Month Forecast
Average Price Target
C$10.51
▲(141.02% Upside)
Technical Analysis
Oncolytics Biotech
―
Knight Therapeutics
―
Cardiol Therapeutics
―
Quantum Numbers
―
Best Analysts Covering APS
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-61.18%
reiterated a buy rating 10 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -61.18% per trade.
---